Recent advances in the field of genetic engineering are expanding the capability of gene therapy to treat diseases, notably those previously unreachable. As a proof, the last two years saw the number of marketing authorization for gene therapy products significantly rise. Last month, Novartis has obtained Canadian approvement for its CAR-T Therapy, Kymriah.
For its second edition of its review Drug Discovery and Evaluation: Methods in Clinical Pharmacology, the editor Springer decided to add new chapters such as pain, addiction, orphan diseases, gene therapy. It demonstrates the increasing interest for these fields. Nicolas Grandchamp from GEG-Tech wrote the chapter on Human gene therapy. It provides a state of the art, and discusses the recent marketing approvals as well as their issues and challenges.
Feel free to contact us if you want to know more about our publication.
